Intelligence Feed event · Equity · 2026-09-03

    Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R Progress

    Question

    Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R Progress

    Direct answer

    Nxera Pharma confirmed an $8.6 million milestone receipt from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonists. The cash inflow will be booked as Q3 2026 revenue by Nxera. For Eli Lilly, advancing OX2R candidates expands its pipeline exposure in sleep and neurological disorders, supporting long-term non-GLP-1 pipeline diversification.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R Progress”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nxera-earns-8-6m-milestone-from-eli-lilly-subsidiary-on-late-stage-ox2r-progress-63652b

    EQUITY
    Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R Progress
    Nxera Pharma confirmed an $8.6 million milestone receipt from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonists. The cash inflow will be booked as Q3 2026 revenue by Nxera. For Eli Lilly, advancing OX2R candidates expands its pipeline exposure in sleep and neurological disorders, supporting long-term non-GLP-1 pipeline diversification.
    LLY
    Impact
    62
    SEP 3
    SIG
    88%
    LLY
    Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R Progress
    Nxera Pharma confirmed an $8.6 million milestone receipt from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonists. The cash inflow will be booked as Q3 2026 revenue by Nxera. For Eli Lilly, advancing OX2R candidates expands its pipeline exposure in sleep and neurological disorders, supporting long-term non-GLP-1 pipeline diversification.
    → Pipeline derisking for orexin receptor 2 agonists reinforces Eli Lilly's neuroscience pipeline valuation within large-cap biopharma.
    Impact
    Nxera Pharma confirmed an $8.6 million milestone receipt from Eli Lilly subsidiary Centessa Pharmaceuticals following late-stage clinical progress on selective orexin receptor 2 (OX2R) agonists. The cash inflow will be booked as Q3 2026 revenue by Nxera. For Eli Lilly, advancing OX2R candidates expands its pipeline exposure in sleep and neurological disorders, supporting long-term non-GLP-1 pipeline diversification.
    Affected
    LLY
    Transmission
    Pipeline derisking for orexin receptor 2 agonists reinforces Eli Lilly's neuroscience pipeline valuation within large-cap biopharma.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYneuroscience clinical pipeline advancementUp1-4wNxera Pharma receives $8.6M milestone from Eli Lilly subsidiary Centessa on OX2R candidate progress.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month